Influenza a Neuraminidase-Based Bivalent mRNA Vaccine Induces Th1-Type Immune Response and Provides Protective Effects in Mice

Mingyang Li,Mengyuan Liu,Shaohui Song,Ruirui Zhao,Yun Xie,Jing Liu,Lilan Xu,Xuefeng Ma,Mingyu Song,Jian Zhou,Guoyang Liao

DOI: https://doi.org/10.3390/vaccines12030300

2024-03-13

Vaccines

Abstract:Vaccines are one of the most effective means of preventing influenza A, typically containing the hemagglutinin (HA) of the influenza A virus. However, antigenic drift and shift of the influenza A virus can lead to instability in vaccine efficacy. Compared to HA, the antigenic variation rate of neuraminidase (NA) is slower. In traditional inactivated influenza vaccines, although they contain a certain amount of NA, there are significant differences between different batches, which cannot consistently induce NA-based immune responses. Therefore, NA is often overlooked in vaccine development. In this study, we report an mRNA vaccine encoding the NA of two strains of influenza A virus. The experimental results demonstrated that when matched with the viral strain, this mRNA vaccine induced high levels of neutralizing antibodies, providing a protective effect to mice in viral challenge experiments, and this immune response was shown to be biased towards the Th1 type. In summary, this study demonstrates that NA is a promising potential antigen, providing new insights for the development of influenza A virus vaccines.

immunology,medicine, research & experimental

What problem does this paper attempt to address?

The problems that this paper attempts to solve are the effectiveness and stability of influenza virus vaccines. Specifically:

1. **Antigenic variation leads to unstable vaccine efficacy**: The hemagglutinin (HA) antigen of the influenza virus has a high mutation rate, which may lead to a mismatch between the vaccine and the prevalent virus strains, thereby reducing or nullifying the effectiveness of the vaccine.
2. **Long production cycle**: Traditional influenza vaccines rely on complex biological processes, such as egg - based or cell - culture - based methods, and usually require a production cycle of more than six months, which limits the supply and distribution of influenza vaccines.
3. **Limited applicability in specific populations**: The immunogenicity and safety of influenza vaccines may vary among different populations, such as the elderly, children, pregnant women, and the immunocompromised. Evaluation and adjustment of vaccine efficacy and safety are required for these groups.

To address the above challenges, researchers designed a bivalent mRNA vaccine based on the influenza virus neuraminidase (NA). Compared with HA, the antigenic variation rate of NA is slower. However, in traditional inactivated influenza vaccines, there are significant differences in the NA content, and it is unable to consistently induce NA - based immune responses. Therefore, NA is often overlooked in vaccine development.

This study aims to evaluate whether this mRNA vaccine can induce high - titer neutralizing antibodies and provide protection in mice by encoding the NA sequences of two influenza virus strains. The experimental results show that this mRNA vaccine can not only induce high - level neutralizing antibodies but also provide protection in virus challenge experiments, and the immune response is skewed towards the Th1 type. This indicates that NA is a potential antigen and provides new insights for the design and improvement of influenza virus vaccines.